

**Amendments to the Claims**

The listing of claims set forth below will replace all prior versions and listings of claims in the application.

1-37 (Canceled).

38. (Currently Amended) A method of treating ~~or preventing~~ the inflammatory response of ulcerative colitis in a subject comprising administering to the subject an effective amount of a substance ~~that modulates NK-T cell activity that binds NK-T cells or antigen presenting cells and reduces the number of NK-T cells in the subject or inhibits NK-T cell activation by antigen presenting cells.~~

39. (Previously Presented) The method of claim 38, wherein the substance modulates NK-T cell activity by reducing NK-T cell activity.

40. (Previously Presented) The method of claim 38, wherein the substance modulates NK-T cell activity by maintaining a level of NK-T cell activity.

41. (Previously Presented) The method of claim 38, wherein the subject is a mouse.

42. (Previously Presented) The method of claim 38, wherein the subject is a human.

43-44 (Canceled)

45. (Currently Amended) The method of claim 38, wherein the ulcerative colitis is oxazolone colitis.

46. (Currently Amended) The method of claim 38, wherein the substance ~~that modulates NK-T cell activity~~ is an antibody.

47-48 (Canceled)

49. (Withdrawn) The method of ~~claim 47~~claim 46, wherein the antibody binds to CD1.

50. (Withdrawn) The method of ~~claim 47~~claim 46, wherein the antibody binds to V $\alpha$ 14 J $\alpha$ 281.

51. (Withdrawn) The method of ~~claim 47~~claim 46, wherein the antibody binds to V $\alpha$ 24 J $\alpha$ 18.

52. (Currently Amended) A method of treating ~~or preventing~~ the inflammatory response of ulcerative colitis in a subject comprising administering to the subject an effective amount

of a substance that modulates IL-13 activity a substance that binds to IL-13, wherein the substance inhibits IL-13 activation of IL-13Ra.

53-64 (Canceled)

65. (Previously Presented) The method of claim 52, wherein the subject is a mouse.

66. (Previously Presented) The method of claim 52, wherein the subject is a human.

67-68 (Canceled)

69. (Currently Amended) The method of claim 52, wherein the ulcerative colitis is oxazolone colitis.

70. (Canceled)

71. (Currently Amended) The method of claim 52, wherein the substance that binds to modulates IL-13 activity is an antibody.

72. (Withdrawn) The method of claim 52, wherein the substance binds to IL-13 is IL-13 $\alpha$ Ra2-Fc.

73-74 (Canceled)

75. (Withdrawn) A method of screening a substance for effectiveness in reducing the inflammatory response of ulcerative colitis by inhibiting modulating NK-T cell activity comprising:

- a) obtaining an animal having ulcerative colitis;
- b) administering the substance to an animal;
- c) assaying the animal for an effect on NK-T cell activity which results in the reduction of the inflammatory response of the ulcerative colitis, thereby identifying a substance effective in reducing the inflammatory response of ulcerative colitis by inhibiting modulating NK-T cell activity.

76. (Withdrawn) The method of claim 75, wherein the animal is a mouse.

77. (Canceled)

78. (Withdrawn) The method of claim 75, wherein the animal has an established ulcerative colitis produced by introducing into the colon of the animal an effective amount of a hapten reagent.

**ATTORNEY DOCKET NO. 14014.0410U1**  
**Application No. 10/517,898**

79. (Withdrawn) The method of claim 75, wherein the hapten reagent is oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one).
80. (Withdrawn) The method of screening a substance for effectiveness in reducing the inflammatory response of ulcerative colitis by inhibiting modulating IL-13 activity comprising:
  - a) obtaining an animal having ulcerative colitis;
  - b) administering the substance to an animal;
  - c) assaying the animal for an effect on IL-13 activity which results in the reduction of the inflammatory response of the ulcerative colitis, thereby identifying a substance effective in reducing the inflammatory response of ulcerative colitis by inhibiting modulating IL-13 activity.
81. (Withdrawn) The method of claim 80, wherein the animal is a mouse.
82. (Canceled)
83. (Withdrawn) A method of screening for a substance effective in preventing the inflammatory response of ulcerative colitis by inhibiting modulating IL-13 activity comprising:
  - a) administering the substance to an animal susceptible to ulcerative colitis;
  - b) subjecting the animal to treatment that will induce an inflammatory response; and
  - c) assaying inflammatory tissue cells from the animal for an amount of secretion of IL-13, whereby a decrease or lack of increase in the amount of IL-13 in the inflammatory tissue cells of the animal as compared to an increase in the amount of IL-13 in a control animal having ulcerative colitis in the absence of the substance identifies a substance that is effective in preventing the inflammatory response of ulcerative colitis by inhibiting modulating IL-13 activity.
84. (Withdrawn) A method of screening for a substance effective in preventing the inflammatory response of ulcerative colitis by inhibiting modulating NK-T cell activity comprising:
  - a) administering the substance to an animal susceptible to ulcerative colitis;
  - b) subjecting the animal to treatment that will induce an inflammatory response; and

- c) assaying the animal for an effect on NK-T cell activity, whereby a decrease or lack of increase in NK-T cell activity in the inflammatory tissue cells of the animal as compared to an increase in NK-T cell activity in a control animal having ulcerative colitis in the absence of the substance identifies a substance that is effective in preventing the inflammatory response of ulcerative colitis by inhibiting modulating NK-T cell activity.
- 85. (New) The method of claim 52, wherein the method further comprises administering to the subject an effective amount of an antibody that binds to IL-13R $\alpha$ 2.